CLINICAL STUDIES: ELECTROPHYSIOLOGY
Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation
A randomized, double-blind, placebo-controlled study
Volker Kühlkamp*,
Alexander Schirdewan ,
Karl Stangl ,
Michael Homberg ,
Matthias Ploch|| and
Otto A. Beck¶
* Eberhard-Karls-Universität, Tübingen, Germany
Franz-Volhard-Klinik, Humboldt-Universität, Berlin, Germany
Charité, Humboldt-Universität, Berlin, Germany
Krankenhaus Maria Hilf, Mönchengladbach, Germany
|| St. Antonius Hospital, Eschweiler, Germany
¶ Kreiskrankenhaus, Peine, Germany
Manuscript received April 27, 1999;
revised manuscript received February 11, 2000,
accepted March 6, 2000.
Reprint requests and correspondence: Volker Kühlkamp, Eberhard-Karls-Universität, Medizinische Klinik III, Otfried Müller Strasse 10, 72076 Tübingen, Germany
volker.kuehlkamp{at}med.uni-tuebingen.de
OBJECTIVES
The primary objective of the present study was to assess the efficacy of metoprolol CR/XL to reduce the risk of relapse after cardioversion of persistent atrial fibrillation to sinus rhythm.
BACKGROUND
Indirect data from studies with d,l sotalol provide evidence that the beta-blocking effects of the compound are important in maintaining sinus rhythm after cardioversion of atrial fibrillation.
METHODS
After successful conversion to sinus rhythm, 394 patients with a history of persistent atrial fibrillation were randomly assigned to treatment with metoprolol CR/XL or placebo. The two treatment groups were similar with respect to all pretreatment characteristics. Patients were seen on an outpatient basis for recording of resting electrocardiogram (ECG) after one week, one, three and six months of follow-up or whenever they felt that they had a relapse into atrial fibrillation or experienced an adverse event.
RESULTS
In the metoprolol CR/XL group, 96 patients (48.7%) had a relapse into atrial fibrillation compared with 118 patients (59.9%) in the placebo group (p = 0.005). Heart rate in patients after a relapse into atrial fibrillation was significantly lower in the metoprolol group (98 ± 23 beats/min) than in the placebo group (107 ± 27 beats/min). The rate of adverse events reported was similar in both groups when the difference in follow-up time was taken into account.
CONCLUSIONS
The results of this double-blind, placebo-controlled study in patients after cardioversion of persistent atrial fibrillation showed that metoprolol CR/XL was effective in preventing relapse into atrial fibrillation or flutter.
|
Abbreviations and Acronyms
| | DC | = direct current | | ECG | = electrocardiogram |
|
This article has been cited by other articles:
|
|
|
|
 
G. Casaclang-Verzosa, B. J. Gersh, and T. S.M. Tsang
Structural and functional remodeling of the left atrium: clinical and therapeutic implications for atrial fibrillation.
J. Am. Coll. Cardiol.,
January 1, 2008;
51(1):
1 - 11.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H.-R. Neuberger, C. Mewis, D. J. van Veldhuisen, U. Schotten, I. C. van Gelder, M. A. Allessie, and M. Bohm
Management of atrial fibrillation in patients with heart failure
Eur. Heart J.,
November 1, 2007;
28(21):
2568 - 2577.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K Nergardh, M. Rosenqvist, R. Nordlander, and M. Frick
Maintenance of sinus rhythm with metoprolol CR initiated before cardioversion and repeated cardioversion of atrial fibrillation: a randomized double-blind placebo-controlled study
Eur. Heart J.,
June 1, 2007;
28(11):
1351 - 1357.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Rivard, H. Sinno, A. Shiroshita-Takeshita, G. Schram, T.-K. Leung, and S. Nattel
The pharmacological response of ischemia-related atrial fibrillation in dogs: Evidence for substrate-specific efficacy
Cardiovasc Res,
April 1, 2007;
74(1):
104 - 113.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. A. Nasr, A. Bouzamondo, J.-S. Hulot, O. Dubourg, J.-Y. Le Heuzey, and P. Lechat
Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis
Eur. Heart J.,
February 8, 2007;
(2007)
ehl484v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Lombardi, M. Borggrefe, W. Ruzyllo, B. Luderitz, and for the A-COMET-II Investigators
Azimilide vs. placebo and sotalol for persistent atrial fibrillation: the A-COMET-II (Azimilide-CardiOversion MaintEnance Trial-II) trial
Eur. Heart J.,
September 2, 2006;
27(18):
2224 - 2231.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Writing Committee Members, V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, et al.
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
Europace,
September 1, 2006;
8(9):
651 - 745.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al.
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
J. Am. Coll. Cardiol.,
August 15, 2006;
48(4):
854 - 906.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al.
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
J. Am. Coll. Cardiol.,
August 15, 2006;
48(4):
e149 - e246.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al.
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
Circulation,
August 15, 2006;
114(7):
e257 - e354.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al.
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
Circulation,
August 15, 2006;
114(7):
700 - 752.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Authors/Task Force Members, V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, et al.
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
Eur. Heart J.,
August 2, 2006;
27(16):
1979 - 2030.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Lafuente-Lafuente, S. Mouly, M. A. Longas-Tejero, I. Mahe, and J.-F. Bergmann
Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials.
Arch Intern Med,
April 10, 2006;
166(7):
719 - 728.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. N. Singh
{beta}-Adrenergic Blockers as Antiarrhythmic and Antifibrillatory Compounds: An Overview
Journal of Cardiovascular Pharmacology and Therapeutics,
October 1, 2005;
10(4_suppl):
S3 - S14.
[Abstract]
[PDF]
|
|
|
|
|
|
|
N. Wadhani and B. N. Singh
Prolongation of Repolarization as Antifibrillatory Action Revisited: Drug Combination Therapy in Atrial Fibrillation
Journal of Cardiovascular Pharmacology and Therapeutics,
July 1, 2005;
10(3):
149 - 152.
[PDF]
|
|
|
|
|
|
|
R. L. Page
Newly Diagnosed Atrial Fibrillation
N. Engl. J. Med.,
December 2, 2004;
351(23):
2408 - 2416.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Task Force Members, J. Lopez-Sendo, K. Swedberg, J. McMurray, J. Tamargo, A. P. Maggioni, H. Dargie, M. Tendera, F. Waagstein, J. Kjekshus, et al.
Expert consensus document on {beta}-adrenergic receptor blockers: The Task Force on Beta-Blockers of the European Society of Cardiology
Eur. Heart J.,
August 1, 2004;
25(15):
1341 - 1362.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Van Noord, R. G. Tieleman, H. A. Bosker, T. Kingma, D. J. Van Veldhuisen, H. J.G.M Crijns, and I. C. Van Gelder
Beta-blockers prevent subacute recurrences of persistent atrial fibrillation only in patients with hypertension
Europace,
January 1, 2004;
6(4):
343 - 350.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Waagstein, O. Stromblad, B. Andersson, M. Bohm, M. Darius, W. Delius, F. Goss, K.J. Osterziel, M. Sigmund, S.-P. Trenkwalder, et al.
Increased exercise ejection fraction and reversed remodeling after long-term treatment with metoprolol in congestive heart failure: a randomized, stratified, double-blind, placebo-controlled trial in mild to moderate heart failure due to ischemic or idiopathic dilated cardiomyopathy
Eur J Heart Fail,
October 1, 2003;
5(5):
679 - 691.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Capucci and D. Aschieri
Antiarrhythmic drug therapy: what is certain and what is to come
Eur. Heart J. Suppl.,
September 1, 2003;
5(suppl_H):
H8 - H18.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. Dorian and I. Mangat
Restoring sinus rhythm in atrial fibrillation: A pyrrhic victory?
J. Am. Coll. Cardiol.,
July 2, 2003;
42(1):
30 - 32.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Valenzuela
Pharmacological electrical remodelling in human atria induced by chronic {beta}-blockade
Cardiovasc Res,
June 1, 2003;
58(3):
498 - 500.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J Workman, K. A Kane, J. A Russell, J. Norrie, and A. C Rankin
Chronic beta-adrenoceptor blockade and human atrial cell electrophysiology: evidence of pharmacological remodelling
Cardiovasc Res,
June 1, 2003;
58(3):
518 - 525.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Page, T. W. Tilsch, S. J. Connolly, D. J. Schnell, S. R. Marcello, W. E. Wilkinson, E. L.C. Pritchett, and for the Azimilide Supraventricular Arrhythmia Prog
Asymptomatic or "Silent" Atrial Fibrillation: Frequency in Untreated Patients and Patients Receiving Azimilide
Circulation,
March 4, 2003;
107(8):
1141 - 1145.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. H. Madrid, M. G. Bueno, J. M.G. Rebollo, I. Marin, G. Pena, E. Bernal, A. Rodriguez, L. Cano, J. M. Cano, P. Cabeza, et al.
Use of Irbesartan to Maintain Sinus Rhythm in Patients With Long-Lasting Persistent Atrial Fibrillation: A Prospective and Randomized Study
Circulation,
July 16, 2002;
106(3):
331 - 336.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. S. Aronow
Management of the Older Person With Atrial Fibrillation
J. Gerontol. A Biol. Sci. Med. Sci.,
June 1, 2002;
57(6):
M352 - 363.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
S. Nattel
Therapeutic implications of atrial fibrillation mechanisms: can mechanistic insights be used to improve AF management?
Cardiovasc Res,
May 1, 2002;
54(2):
347 - 360.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Fuster, L. E. Ryden, R. W. Asinger, D. S. Cannom, H. J. Crijns, R. L. Frye, J. L. Halperin, G. N. Kay, W. W. Klein, S. Levy, et al.
ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology
Circulation,
October 23, 2001;
104(17):
2118 - 2150.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology
Eur. Heart J.,
October 2, 2001;
22(20):
1852 - 1923.
[PDF]
|
|
|
|
|
|
|
V. Fuster, L. E. Ryden, R. W. Asinger, D. S. Cannom, H. J. Crijns, R. L. Frye, J. L. Halperin, G. N. Kay, W. W. Klein, S. Levy, et al.
ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary: A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology
J. Am. Coll. Cardiol.,
October 1, 2001;
38(4):
1231 - 1265.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Fuster, L. E. Ryden, R. W. Asinger, D. S. Cannom, H. J. Crijns, R. L. Frye, J. L. Halperin, G. N. Kay, W. W. Klein, S. Levy, et al.
ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology
J. Am. Coll. Cardiol.,
October 1, 2001;
38(4):
1266 - 1266.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Coumel
Sotalol: a fool's deal?
Eur. Heart J.,
August 2, 2001;
22(16):
1370 - 1373.
[PDF]
|
|
|
|
|
|
|
R. L. Page, J. A. Reiffel, and M. E. Tavel
Asymptomatic Atrial Fibrillation : Problems of Management
Chest,
February 1, 2001;
119(2):
628 - 631.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Beta-Blocker Reduces Recurrence of Atrial Fib After Cardioversion
Journal Watch (General),
July 28, 2000;
2000(728):
4 - 4.
[Full Text]
|
|
|
|
